Compare Citius Pharmaceuticals Inc (CTXR) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Visa Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.52 (market cap $14.64M), while Visa Inc trades at $355.52 (market cap $677.06B). The key difference: Visa Inc is far larger — about 46247.3× Citius Pharmaceuticals Inc's market cap, and Visa Inc pays a 0.75% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | V | |
|---|---|---|
Market Cap | $14.64M | $677.06B |
Sector | Health | Financials |
52-Week High | $1.82 | $362.13 |
52-Week Low | $0.53 | $295.52 |
Enterprise Value | $10.86M | $687.65B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $357.75, up 2.52% today, with a bullish technical signal and strong fundamentals. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $3.31 exceeding the $3.10 estimate. Revenue grew to $40.0 billion in 2025, and net income margin remains robust at 51.68%. The stock is near its pivot point of $357, with support at $354 and resistance at $360. Analysts maintain a strong buy consensus, with an average price target of $394.50.
The outlook for Visa is positive, driven by earnings momentum and strategic initiatives like AI-powered commerce tools. However, risks include competitive pressures from fintech and regulatory scrutiny. With 85% of analysts rating it a buy and institutional holdings increasing, the stock offers growth potential but requires monitoring of payment industry disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
